Literature DB >> 1995731

Recombinant murine granulocyte-macrophage colony-stimulating factor augments neutrophil recovery and enhances resistance to infections in myelosuppressed mice.

P Mayer1, E Schütze, C Lam, F Kricek, E Liehl.   

Abstract

The ability of recombinant murine granulocyte-macrophage colony-stimulating factor (rmGM-CSF) to protect myelosuppressed mice against lethal infections was evaluated. In mice myelosuppressed by cyclophosphamide, subcutaneously administered rmGM-CSF was a potent stimulus of granulopoiesis by increasing the number of GM-CSF-responsive precursor cells in bone marrow followed by a profound neutrophilia. Neutrophil recovery was augmented by rmGM-CSF in a dose-dependent manner at daily doses of 0.6-5.0 micrograms/mouse. In addition, rmGM-CSF increased the functional activity of circulating neutrophils at similar doses. When rmGM-CSF was administered to neutropenic mice before experimentally induced Pseudomonas aeruginosa, Staphylococcus aureus, or Candida albicans infections, it protected against these lethal infections, resulting in increased numbers of survivors. These data suggest that rmGM-CSF protects neutropenic mice from lethal infections, probably by augmenting neutrophil recovery after myelosuppression and activation of mature cells.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1995731     DOI: 10.1093/infdis/163.3.584

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  16 in total

Review 1.  Osteoblast responses to bacterial pathogens: a previously unappreciated role for bone-forming cells in host defense and disease progression.

Authors:  Ian Marriott
Journal:  Immunol Res       Date:  2004       Impact factor: 2.829

2.  Recombinant Granulocyte-Macrophage Colony-Stimulating Factor (rGM-CSF) : A Review of its Pharmacological Properties and Prospective Role in the Management of Myelosuppression.

Authors:  Susan M Grant; Rennie C Heel
Journal:  Drugs       Date:  1992-04       Impact factor: 9.546

3.  Immunostimulatory human urinary protein.

Authors:  E Fontan; H Saklani-Jusforgues; R M Fauve
Journal:  Proc Natl Acad Sci U S A       Date:  1992-05-15       Impact factor: 11.205

4.  Influence of cystic fibrosis transmembrane conductance regulator on gene expression in response to Pseudomonas aeruginosa infection of human bronchial epithelial cells.

Authors:  Nina Reiniger; Jeffrey K Ichikawa; Gerald B Pier
Journal:  Infect Immun       Date:  2005-10       Impact factor: 3.441

Review 5.  The potential role of granulocyte-macrophage colony stimulating factor in therapy of fungal infections: a commentary.

Authors:  G P Bodey
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1994-05       Impact factor: 3.267

6.  Rhino-orbital-cerebral mucormycosis.

Authors:  Maria N Gamaletsou; Nikolaos V Sipsas; Emmanuel Roilides; Thomas J Walsh
Journal:  Curr Infect Dis Rep       Date:  2012-08       Impact factor: 3.725

Review 7.  Antifungal agents in the 1990s. Current status and future developments.

Authors:  C A Kauffman; P L Carver
Journal:  Drugs       Date:  1997-04       Impact factor: 9.546

Review 8.  Prediction of the role of granulocyte-macrophage colony-stimulating factor in animals and man from in vitro results.

Authors:  E Liehl; J Hildebrandt; C Lam; P Mayer
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1994       Impact factor: 3.267

9.  Selective early production of CCL20, or macrophage inflammatory protein 3alpha, by human mast cells in response to Pseudomonas aeruginosa.

Authors:  Tong-Jun Lin; Lauren H Maher; Kaede Gomi; Jeffrey D McCurdy; Rafael Garduno; Jean S Marshall
Journal:  Infect Immun       Date:  2003-01       Impact factor: 3.441

10.  Granulocyte macrophage colony-stimulating factor improves survival in two models of gut-derived sepsis by improving gut barrier function and modulating bacterial clearance.

Authors:  R Gennari; J W Alexander; L Gianotti; T Eaves-Pyles; S Hartmann
Journal:  Ann Surg       Date:  1994-07       Impact factor: 12.969

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.